BNP Paribas Asset Management Holding S.A. - BIOMARIN PHARMACEUTICAL INC ownership

BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP Paribas Asset Management Holding S.A. ownership history of BIOMARIN PHARMACEUTICAL INC
ValueSharesWeighting
Q3 2023$3,420
-0.5%
3,500,0000.0%0.01%
-9.1%
Q2 2023$3,438
-2.9%
3,500,0000.0%0.01%
-8.3%
Q1 2023$3,541
-5.7%
3,500,0000.0%0.01%
-7.7%
Q4 2022$3,755
-99.9%
3,500,0000.0%0.01%
-7.1%
Q3 2022$3,532,000
-95.0%
3,500,000
-16.2%
0.01%
-94.8%
Q2 2022$70,578,000
+1924.6%
4,175,000
+19.3%
0.27%
+2141.7%
Q1 2022$3,486,000
-95.3%
3,500,000
-16.2%
0.01%
-95.2%
Q4 2021$74,141,000
+1.6%
4,175,0000.0%0.25%
-8.5%
Q3 2021$72,948,000
-0.9%
4,175,0000.0%0.27%
+3.4%
Q2 2021$73,603,000
+1949.7%
4,175,000
+19.3%
0.26%
+1646.7%
Q1 2021$3,591,000
-4.0%
3,500,0000.0%0.02%
-11.8%
Q4 2020$3,740,000
+2.0%
3,500,0000.0%0.02%
-19.0%
Q3 2020$3,668,000
-14.4%
3,500,0000.0%0.02%
-27.6%
Q2 2020$4,285,000
+18.1%
3,500,0000.0%0.03%
-6.5%
Q1 2020$3,628,000
-1.7%
3,500,0000.0%0.03%
+24.0%
Q4 2019$3,690,000
+6.4%
3,500,0000.0%0.02%
-7.4%
Q3 2019$3,467,000
-4.3%
3,500,0000.0%0.03%
-10.0%
Q2 2019$3,624,000
+1.3%
3,500,0000.0%0.03%0.0%
Q1 2019$3,576,0003,500,0000.03%
Other shareholders
BIOMARIN PHARMACEUTICAL INC shareholders Q3 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 53,670$57,726,0003.34%
SHENKMAN CAPITAL MANAGEMENT INC 26,959,000$29,149,0003.04%
ADVENT CAPITAL MANAGEMENT /DE/ 84,134,000$90,539,0001.93%
Cheyne Capital Management (UK) LLP 3,220,000$3,452,0001.75%
PFM Health Sciences, LP 40,300,000$43,210,0001.52%
Sonora Investment Management, LLC 6,370,000$6,807,0000.56%
MACKAY SHIELDS LLC 66,018,000$70,980,0000.49%
ZAZOVE ASSOCIATES LLC 1,500,000$1,608,0000.20%
IRON Financial LLC 275,000$295,0000.15%
PALISADE CAPITAL MANAGEMENT, LP 3,000,000$3,216,0000.08%
View complete list of BIOMARIN PHARMACEUTICAL INC shareholders